CRMD

CorMedix Inc

7.85

Oct 23 • 3:59 PM ET -0.25 (-3.09%)

7.75

Aftermarket • 7:30 PM ET -0.10 (-1.27%)

Healthcare Biotechnology USA Small NASD

Peers: ARDX CTXR SPRO PYPD UNCY HRTX PHAT PCRX PLX ICU

| Held by: AVUV VTI IWM XPH VXF IWN CALF VTWO SCHA FDM

Scroll to Statements

Index	RUT
Market Cap	611.83M
Enterprise Value	499.63M
Income	187.17M
Sales	462.25M
Book/sh	5.93
Cash/sh	3.30
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	191
IPO	May 13, 2010

P/E	3.73
Forward P/E	137.12
PEG	-
P/S	1.32
P/B	1.32
P/C	2.38
P/FCF	2.45
EV/EBITDA	1.98
EV/Sales	1.08
Quick Ratio	2.36
Current Ratio	2.56
Debt/Eq	0.31
LT Debt/Eq	0.31
Option/Short	Yes / Yes

EPS (ttm)	2.10
EPS next Y	0.06
EPS next Q	-0.10
EPS this Y	-75.71%
EPS next Y	-88.44%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	1582.83% 319.75%
EPS Y/Y TTM	210.82%
Sales Y/Y TTM	280.50%
EPS Q/Q	1.92%
Sales Q/Q	156.52%
Earnings	Aug 13 BMO
EPS/Sales Surpr.	21.85% 6.13%

Insider Own	8.29%
Insider Trans	0.00%
Inst Own	56.95%
Inst Trans	2.70%
ROA	32.36%
ROE	54.93%
ROIC	30.89%
Gross Margin	82.78%
Oper. Margin	46.95%
Profit Margin	40.49%
SMA20	4.46%
SMA50	-0.01%
SMA200	2.38%
Trades

Shs Outstand	77.67M
Shs Float	71.48M
Short Float	21.58%
Short Ratio	13.77
Short Interest	15.42M
52W High	13.02 -39.71%
52W Low	6.12 28.16%
Volatility	4.14% 3.46%
ATR (14)	0.28
RSI (14)	55.91
Beta	1.44
Rel Volume	0.80
Avg Volume	1.12M
Volume	894,557

Perf Week	8.13%
Perf Month	1.03%
Perf Quarter	3.29%
Perf Half Y	5.80%
Perf YTD	-32.50%
Perf Year	-30.59%
Perf 3Y	149.21%
Perf 5Y	65.26%
Perf 10Y	-29.60%
Recom	1.00
Target Price	14.60
Prev Close	8.10
Price	7.85
Change %	-3.09%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-26	Initiated	Oppenheimer	Outperform	$15
Oct-20-25	Upgrade	D. Boral Capital	Hold → Buy	$14
Jun-30-25	Initiated	H.C. Wainwright	Buy	$20
Jun-30-25	Downgrade	D. Boral Capital	Buy → Hold
Mar-07-25	Initiated	Leerink Partners	Outperform	$18
Jan-13-25	Initiated	D. Boral Capital	Buy	$15
Aug-26-24	Initiated	Rodman & Renshaw	Buy	$13
Aug-10-23	Initiated	RBC Capital Mkts	Outperform	$6
Feb-17-21	Initiated	Needham	Buy	$31
Sep-29-20	Initiated	JMP Securities	Mkt Outperform	$22
Sep-21-20	Initiated	Truist	Buy	$20
Dec-18-19	Initiated	B. Riley FBR	Buy	$48
Mar-26-19	Reiterated	H.C. Wainwright	Buy	$3 → $15
Dec-06-18	Initiated	ROTH Capital	Buy	$6
Sep-25-17	Reiterated	H.C. Wainwright	Buy	$3 → $4
Aug-10-17	Reiterated	Rodman & Renshaw	Buy	$5 → $3
May-05-17	Reiterated	Rodman & Renshaw	Buy	$6 → $5
Nov-11-16	Reiterated	FBR & Co.	Outperform	$6 → $4
Mar-17-16	Reiterated	FBR Capital	Outperform	$7 → $6
Mar-03-16	Initiated	FBR Capital	Outperform	$7

Show Previous Ratings

Oct-19-26 07:30AM	Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo (Rezafungin) for Prophylaxis of Invasive Fungal Diseases (GlobeNewswire)
Oct-15-26 07:30AM	Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer (PR Newswire)
Sep-01-26 08:30AM	CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-13-26 07:08PM	Cormedix Inc (CRMD) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised EBITDA ... (GuruFocus.com) +14.65% -7.37%
11:04AM	CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat (Stocktwits)
07:40AM	Loading…
07:40AM	CorMedix: Q2 Earnings Snapshot (Associated Press)
07:30AM	Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-26 08:30AM	CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026 (GlobeNewswire)
Jun-08-26 08:30AM	U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin Patent Litigation (GlobeNewswire)
May-15-26 08:30AM	Cormedix Therapeutics to Participate in two Upcoming Investor Conferences (GlobeNewswire)
May-14-26 07:02PM	Cormedix Inc (CRMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) +5.73%
10:06AM	CorMedix Shares Jump After Revenue Beat and Higher Full-Year Guidance (InvestorsHub)
07:37AM	CorMedix: Q1 Earnings Snapshot (Associated Press)
07:30AM	Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-05-26 08:30AM	CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026 (GlobeNewswire)
07:30AM	Loading…
Apr-27-26 07:30AM	CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients (GlobeNewswire) +5.39%
Apr-07-26 08:30AM	CorMedix to Participate in Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-05-26 08:18PM	CorMedix Q4 Earnings Call Highlights (MarketBeat) -11.52%
04:04PM	Cormedix Inc (CRMD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
08:50AM	CorMedix (CRMD) Lags Q4 Earnings Estimates (Zacks)
07:56AM	CorMedix: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-02-26 08:30AM	CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 (GlobeNewswire)
Feb-27-26 08:05AM	ANI Pharmaceuticals (ANIP) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
Feb-26-26 08:05PM	Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-24-26 08:02AM	CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet? (Zacks)
Feb-23-26 10:45AM	Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings? (Zacks)
Feb-17-26 10:30AM	CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock? (Zacks)
Feb-12-26 08:30AM	CorMedix to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-11-26 03:16PM	CorMedix Inc. (CRMD) Board Approves Multi-Year $75M Stock Buyback (Insider Monkey)
08:01AM	Loading…
08:01AM	CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside (Zacks)
Feb-10-26 06:19PM	CorMedix Investor Day: Melinta Deal Fuels Shift to Multi-Product Pharma, Rezzayo Q2 Data Ahead (MarketBeat)
Feb-02-26 08:30AM	CorMedix Therapeutics Announces Share Repurchase Program (GlobeNewswire) +5.28%
Jan-31-26 07:57AM	H.C. Wainwright Signal Clinical Data to Drive CorMedix Inc. (CRMD) Future Over Commercial Performance (Insider Monkey)
Jan-30-26 08:39AM	CRMD Down 31% in a Month: Is This an Indication to Sell the Stock? (Zacks)
Jan-29-26 08:30AM	CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026 (GlobeNewswire)
Jan-23-26 10:59AM	Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption? (Zacks)
Jan-20-26 09:38AM	CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? (Zacks)
Jan-19-26 11:28AM	High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 (MarketBeat)
Jan-15-26 08:38AM	Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings? (Zacks)
Jan-12-26 02:07PM	KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives (Zacks) -6.29%
11:20AM	MDGL Secures Exclusive Global Right for MASH Treatment From PFE (Zacks)
10:14AM	PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates (Zacks)
10:08AM	TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug (Zacks)
09:33AM	Exelixis Posts Preliminary '25 Results, Issues '26 Outlook (Zacks)
09:32AM	INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced (Zacks)
Jan-09-26 11:46AM	AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations (Zacks)
09:40AM	Are Investors Undervaluing CorMedix (CRMD) Right Now? (Zacks)
09:17AM	Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress (Zacks)
08:30AM	CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-26 12:33PM	GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies (Zacks) -32.77%
12:21PM	CNC Deepens Medicaid Strategy With Cityblock Partnership in Illinois (Zacks)
11:09AM	GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug (Zacks)
09:44AM	KRYS Stock Surges 57% in a Year: More Upside Potential in 2026? (Zacks)
08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks)
08:05AM	CorMedix Therapeutics Announces Leadership and Board Updates (GlobeNewswire)
08:00AM	CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates (GlobeNewswire)
Jan-07-26 12:31PM	Select Medical Expands Rehab Footprint Through Vibra Healthcare JV (Zacks)
11:52AM	ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies (Zacks)
11:49AM	JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus (Zacks)
11:45AM	FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug (Zacks)
09:53AM	OTLK Stock Crashes 67% in a Week: Here's What You Need to Know (Zacks)
Jan-06-26 11:53AM	ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH (Zacks) -7.63%
11:47AM	Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? (Zacks)
11:18AM	ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study (Zacks)
10:19AM	INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma (Zacks)
Jan-05-26 10:58AM	Intellia Stock Declines Around 55% in 3 Months: Here's Why (Zacks)
10:28AM	Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026 (Zacks)
10:26AM	FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children (Zacks)
Jan-02-26 11:22AM	Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio (Zacks)
10:54AM	AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation (Zacks)
10:22AM	Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism (Zacks)
08:15AM	INSM Stock Up 78% in 6 Months: Here's What You Need to Know (Zacks)
Dec-31-25 02:42PM	Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months (Zacks) -6.81%
11:24AM	Here's Why You Should Retain Community Health Stock for Now (Zacks)
09:50AM	RARE Rises on Completion of Rolling Submission for AAV Gene Therapy (Zacks)
07:36AM	VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains (Zacks)
Dec-30-25 11:00AM	RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint (Zacks)
07:58AM	Kyverna Therapeutics Stock Up 41% in a Month: Here's Why (Zacks)
Dec-29-25 09:53AM	Ocugen Stock Surges 75% Year to Date: What's in Store for 2026? (Zacks)
09:50AM	MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? (Zacks)
Dec-26-25 09:12AM	Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath? (Zacks)
Dec-24-25 11:22AM	FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug (Zacks)
11:05AM	AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label (Zacks)
09:59AM	Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise (Zacks)
Dec-23-25 03:20PM	Why CorMedix Could be the Biopharma Name to Watch Early in 2026 (MarketBeat)
10:45AM	GILD Exercises Option to License Assembly Bio's Herpes Programs (Zacks)
10:35AM	CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies (Zacks)
10:21AM	JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis (Zacks)
03:13AM	AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised) (Zacks)
Dec-22-25 01:12PM	MarketBeat's Top 5 Rated Small-Cap Stocks (MarketBeat)
11:46AM	BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B (Zacks)
10:25AM	AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use (Zacks)
09:29AM	Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up (Zacks)
Dec-19-25 12:17PM	Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates (Zacks)
10:10AM	MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab (Zacks)
08:59AM	Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dillione Janet	Director	Jan 21 '26	Sale	6.88	10,000	68,800	38,473	Jan 22 09:30 PM
Janet Dillione	Director	Jan 21 '26	Proposed Sale	6.85	10,000	68,502		Jan 21 04:42 PM
Todisco Joseph	Chief Executive Officer	Jan 16 '26	Option Exercise	3.38	29,585	99,997	521,664	Jan 20 09:28 AM
Lefkowitz Steven W	Director	Jan 12 '26	Option Exercise	5.63	15,000	84,450	95,498	Jan 14 09:30 PM
DUNTON ALAN W	Director	Dec 30 '25	Option Exercise	4.03	20,000	80,600	60,250	Jan 02 09:30 PM
DUNTON ALAN W	Director	Dec 30 '25	Sale	13.00	20,000	260,000	40,250	Jan 02 09:30 PM
Alan Dunton	Director	Dec 30 '25	Proposed Sale	12.97	20,000	259,400		Dec 30 04:28 PM
Todisco Joseph	Chief Executive Officer	Dec 18 '25	Option Exercise	4.43	30,000	132,900	539,496	Dec 19 09:30 PM
Todisco Joseph	Chief Executive Officer	Dec 18 '25	Sale	12.00	30,000	360,000	509,496	Dec 19 09:30 PM
Joseph Todisco	Officer	Dec 18 '25	Proposed Sale	11.97	30,000	359,149		Dec 18 04:35 PM
Dillione Janet	Director	Dec 09 '25	Option Exercise	7.82	34,000	265,900	82,473	Dec 11 08:38 AM
Dillione Janet	Director	Dec 09 '25	Sale	12.00	34,000	408,000	48,473	Dec 11 08:38 AM
Lefkowitz Steven W	Director	Dec 09 '25	Sale	11.88	40,000	475,200	80,498	Dec 10 09:38 PM
Janet Dillione	BOD	Dec 09 '25	Proposed Sale	12.00	34,000	408,000		Dec 09 04:43 PM
Lefkowitz Steven W	Director	Dec 09 '25	Proposed Sale	11.26	40,000	450,400		Dec 09 04:27 PM
Dillione Janet	Director	Dec 02 '25	Option Exercise	3.96	46,657	184,802	95,130	Dec 04 09:30 PM
Dillione Janet	Director	Dec 02 '25	Sale	10.00	46,657	466,570	48,473	Dec 04 09:30 PM
Dillione Janet	Director	Nov 24 '25	Option Exercise	3.64	26,343	95,948	74,816	Nov 26 09:30 PM
Dillione Janet	Director	Nov 24 '25	Sale	9.93	26,343	261,586	48,473	Nov 26 09:30 PM
Janet Dillione	Director	Nov 24 '25	Proposed Sale	9.97	73,000	727,927		Nov 24 04:14 PM
Dillione Janet	Director	Nov 14 '25	Sale	11.42	30,000	342,600	48,473	Nov 18 09:45 PM
Dillione Janet	Director	Nov 14 '25	Proposed Sale	10.94	30,000	328,200		Nov 14 12:54 PM
Erin Mistry	Former Officer	Nov 10 '25	Proposed Sale	10.98	13,543	148,719		Nov 10 05:10 PM
Erin Mistry	Former Officer	Nov 06 '25	Proposed Sale	10.97	13,908	152,503		Nov 06 04:27 PM

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CEO & Chairman of the Board of DirectorsMr. Joseph Todisco MBA

Executive VP and Chief Operating & Commercial OfficerMs. Elizabeth Masson-Hurlburt B.A.

EVPMs. Kaufman Beth Zelnick Esq.

EVP & Chief Financial OfficerMs. Susan Blum

SVP & Chief Human Resource OfficerMs. Beth Steinbrenner

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRMD

CorMedix Inc

Upgrade your Finviz experience